Navigation Links
Valeritas Hires Trade and Distribution Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
Date:9/25/2007

Kathy Lang Joins from Auxilium Pharmaceutical as Director, Trade Relations

PARSIPPANY, N.J., Sept. 25 /PRNewswire/ -- Valeritas, LLC, a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that it has hired Kathy Lang to serve as Director of Trade Relations.

Ms. Lang will join the Integrated Healthcare Management Team reporting directly to Matt Nguyen, PharmD. She will play a critical role in developing and executing a trade strategy for Valeritas products in the metabolism arena, with her near term focus on the h-Patch(TM), a once-daily, disposable insulin delivery device that is scheduled for a regional launch in Q1 2008. Ms. Lang will be responsible for managing contracted distribution vendor relationships and services between Valeritas customers and supply chain partners, and will also serve as the primary liaison with pharmacy and trade associations and data sourcing companies. Her additional responsibilities include overseeing/managing inventory issues to ensure adequate product levels are maintained at all times.

As the key driver behind the development of Valeritas' trade strategy, Ms. Lang will play a critical role in the launch of h-Patch(TM).

"Kathy's reputation and experience in the industry is second-to-none," said Robert Gonnelli, President and CEO of Valeritas. "Her past experiences and successes have shown that she has the strategic insight to solidify and validate our approach to managing the h-Patch(TM) distribution through wholesalers."

"I am honored to be part of such an exciting launch of this first-in-class, once-daily disposable insulin delivery device -- which was designed with simplicity-of-use for the end user in mind," said Ms. Lang. "The distribution of the h-Patch(TM) through the traditional pharmacy channel will allow for patients to fulfill their prescription conveniently and to maintain continued compliance of their insulin therapy."

"Kathy's extensive experience within the trade industry working with small and medium size pharmaceutical companies, especially in their early years, will help us be successful as we prepare to launch h-Patch(TM)," added Matt Nguyen, the company's Vice President of Integrated Healthcare Management. "Also, her experience in managing prior product launches with the attention to detail required has garnered her tremendous respect from previous organizations as well as trade customers throughout the distribution channel. She is undoubtedly a great addition to our commercial team."

Ms. Lang joins the company from Auxilium Pharmaceuticals where she was responsible for pharmacy and trade relations that included managing distribution vendors, liaising with data sourcing organizations, pharmacy and trade association relationships, and third-party logistics management. She has more than 18 years of experience in the pharmaceutical industry with roles in sales and sales management and trade relations. The last 12 years were focused in trade relations for Solopak Pharmaceuticals, First Horizon Pharmaceutical Corp., and Auxilium Pharmaceuticals.

About Valeritas, LLC

Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that directly improve clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes.

Valeritas' medical technologies portfolio is headlined by the h-Patch(TM) insulin delivery system. The h-Patch(TM) is a simple-to-use, once-daily disposable basal and on-demand bolus delivery system that will enable the millions suffering from Type 2 diabetes to discreetly and conveniently deliver insulin throughout the day, including around meals. Developed to help enhance a patient's glycemic control, the h-Patch(TM) is the smallest known FDA-cleared insulin delivery system with basal-bolus capability and no visible needle. The h-Patch(TM) has received FDA 510(k) clearance and Phase IV clinical trials are running to support broad marketing and reimbursement claims. In addition to h-Patch(TM) for the delivery of insulin, Valeritas' delivery technology portfolio includes h-Patch(TM) for the delivery of other compounds beyond insulin, and e-Patch(TM) Controlled Release Disposable Micro Pump System, Mini-Ject(TM) Pre-Filled Needle-Free Delivery System and the Micro-Trans(TM) Microneedle Transdermal Delivery Patch. These technologies, when combined with certain compounds, are designed to provide unique products that allow precise dosing in previously difficult-to-treat conditions.

Headquartered in Parsippany, N.J., Valeritas operates its R&D and clinical manufacturing in a state-of-the-art manufacturing and R&D facility in Shrewsbury, Mass.


'/>"/>
SOURCE Valeritas, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Germantown drug company hires pharma veteran James Davidson as COO
2. Merge Healthcare hires new VP of finance
3. PDS hires new VP, buys former health club building
4. Visions: IT exec says CIOs must be ready to help companies ramp up trade
5. Indian trade possibilities boggle the mind
6. Early Stage, Step 4: Cautionary trademark tales
7. SC Johnson issues trademark warning over web offer
8. NameProtect releases annual list of top trademarkers
9. TDS trades markets to gain Duluth presence
10. Chippewa Valley reps hope to score at Twin Cities tradeshow
11. Ruling enforces international trademark electronic filing requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Malden, MA (PRWEB) , ... February 24, 2017 ... ... disc replacement (TDR) procedures can be safely completed in an ambulatory surgery center ... and fusion (ACDF) procedures and previous two-year TDR studies. , Jake Lubinski, ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)...  Driven by consumers, preference towards more natural ... growing categories, finds the recently published U.S. volume ... Multi-regional Market Analysis and Opportunities study by ... "Biotechnology actives are derived from natural ... for skin and hair care applications," explains ...
(Date:2/24/2017)... Feb. 23, 2017 China Biologic Products, Inc. (NASDAQ: ... plasma-based biopharmaceutical company in China, today announced its financial results ... Fourth Quarter 2016 Financial Highlights ... by 21.7% in RMB terms, or increased by 13.6% in ... same quarter of 2015. Gross profit increased ...
Breaking Biology Technology:
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
Breaking Biology News(10 mins):